Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study

References

• Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005; 54: 243–50
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990–2005
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Briasoulis E, Karavasilis V, Fountzilas G, Xeros N, Samelis G, et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?. Acta Oncol 2005; 44: 155–60
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Tsokos M, Fountzilas G, et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications: A Hellenic Cooperative Oncology Group study. Anticancer Res 1998; 18: 1907–14
   PubMed Web of Science ®Google Scholar
• Konecny G. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumour samples. Breast Cancer Res Treat 2001; 67: 223–33
   PubMedGoogle Scholar
• Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N, Fountzilas G. Paclitaxel-Carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy and safety. Med Oncol 2006; 23: 147–60
   PubMedGoogle Scholar
• Vasey PA. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol 2003; 21(Suppl 10)136s–144s
   Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56
   PubMed Web of Science ®Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007; 46: 592–601
   PubMed Web of Science ®Google Scholar
• Hainsworth J, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin and extended schedule etoposide. J Clin Oncol 1997; 15: 2385–93
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II study. The Hellenic Cooperative Oncology Group study. J Clin Oncol 2000; 18: 3101–17
   PubMed Web of Science ®Google Scholar
• Greco FA, Burris HA 3rd, Erland EB, Gray JR, Kalman LA, Schreeder MT, et al. Carcinoma of unknown primary site. Cancer 2000; 89: 2655–60
   PubMed Web of Science ®Google Scholar
• Greco FA, Gray J, Burris HA, Erland JB, Morrissey LH, Hainsworth JD. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 2001; 7: 203–12
   PubMed Web of Science ®Google Scholar
• Bouleuc C, Saghatchian M, Di Tullio L, Louvet Ch, Levy E, Di Palma M, et al. A multicentre phase II study of docetaxel and cisplatin in the treatment of cancer of unknown primary site. Proc Am Soc Clin Oncol 2001;137b:2298.
   Google Scholar
• Gothelf A, Daugaard G, Nelausen K. Paclitaxel, cisplatin and gemcitabine in the treatment of unknown primary tumours, a phase II study. Proc ESMO 2002; 25: 88
   Google Scholar
• Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richard SP, et al. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20: 1651–6
   PubMed Web of Science ®Google Scholar
• Mukai H, Watanabe T, Ando M, Katsumata N. Unknown primary carcinoma: A feasibility assessment of combination chemotherapy with cisplatin and docetaxel. Int J Clin Oncol 2003; 8: 23–5
   PubMedGoogle Scholar
• Greco FA, Rodriguez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA, et al. Carcinoma of unknown primary site: Sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan. A Minnie Pearl Cancer Research Network phase II trial. The Oncologist 2004; 9: 644–52
   PubMed Web of Science ®Google Scholar
• Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 2004; 34: 681–5
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Shields AF, Zalupski M, Heilbrum K, Jain V, Terry D, et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol 2005; 28: 152–6
   PubMed Web of Science ®Google Scholar
• Hainsworth J, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network study. J Clin Oncol 2006; 24: 3548–54
   PubMed Web of Science ®Google Scholar
• Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000; 11: 211–5
   PubMed Web of Science ®Google Scholar
• Berry W, Elkordy M, Rourke O M, Khan M, Asmar L. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: A reasonable regimen for the community-based clinic?. Cancer Invest 2007; 25: 27–31
   PubMed Web of Science ®Google Scholar
• Pouessel D, Culine S, Brecht C, Ychou M, Romieu G, Fabbro M, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004; 100: 1257–61
   PubMed Web of Science ®Google Scholar
• Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of unknown primary site. J Clin Oncol 2002; 20: 4679–83
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, De Bono JS, Kaye SB, Simpson A, Paul J, Brown I, et al. Improved prognosis of patients with intermediate- and poor-risk non seminomatous germ cell tumours by optimising combined treatment. BJU Int 2003; 92: 36–42
   PubMedGoogle Scholar
• Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with poor prognosis metastatic non seminomatous germ cell tumours. J Natl Cancer Inst 1999; 91: 839–46
   PubMedGoogle Scholar
• Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: Missing primary or missing biology?. The Oncologist 2007; 12: 418–25
   PubMed Web of Science ®Google Scholar
• Hainsworth J, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007; 25: 1747–52
   PubMed Web of Science ®Google Scholar